MLX Main

Kills 99.999+% of harmful pathogens in 7 seconds without chemicals!

GermPass patented biotechnology prevents the spread of infectious disease and reduces hospital HAIs

Problem

54,000 people die prematurely every day due to preventable illnesses and 80% of the most common infectious diseases are spread by the hands through germ-infested public touchpoints such as door handles, restroom stalls, elevators, and ATMs

Our solution

Our product forms a sealed germ decontamination chamber around existing public touchpoints. After each touch, the chamber automatically seals allowing UVC LED light to automatically decontaminate the surface in less than 7 seconds.

Target Market

Our technology provides immediate relief to a $38b unaddressed US market for surface-based public germicidal infrastructure.

OUR STORY

2019

Launched

6

Months before COVID-19

1500000

Germs Killed

5

Seconds

WHO IS
MICROLUMIX

The company you have never heard of today. The company you will never forget tomorrow

We launched in September of 2019 and incorporated on 1/1/2020. We tested our first working concept model two weeks before COVID-19 hit the US and we killed 1.5 million germs from a door handle in 5 seconds. Since then, we have killed more than a billion germs in testing.

It's Much Bigger Than

COVID-19

  • COVID-19
  • C. diff
  • MRSA
  • Candida Auris (C. auris)
  • Adenovirus

Touchpoint-Related

Infectious Diseases

  • Norovirus (winter flu)
  • E-coli
  • Klebsiella pneumoniae
  • Streptococcus
  • Listeria Monocytogenes

SICKNESS COSTS EVERYONE

In the US alone, absenteeism costs employers $260b annually. Healthcare-Associated Infections cost another $55b. Medical visits and hospitalizations due to preventable illnesses another $200b.

These factors alone account for $1/2 trillion and this is just within the US. We expect to reduce all these issues significantly and add billions back to the bottom line of public and privately-held organizations around the world.

Employee Absenteeism 260B
Preventable Medical Costs 200B
Hospital Associated Infections 55B
Watch the Harvard Club of New York Launch Event